Crescent Biopharma, Inc.
CBIO
$14.47
-$0.23-1.57%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 580.57% | ||||
| Total Receivables | -- | ||||
| Inventory | -- | ||||
| Prepaid Expenses | 286.80% | ||||
| Finance Division Loans and Leases Current | -- | ||||
| Total Finance Division Other Current Assets | -- | ||||
| Other Current Assets | -- | ||||
| Total Current Assets | 575.31% | ||||
|
|
|||||
| Total Current Assets | 575.31% | ||||
| Net Property, Plant & Equipment | -- | ||||
| Long-term Investments | -- | ||||
| Goodwill | -- | ||||
| Total Other Intangibles | -- | ||||
| Finance Div Loans & Leases LT | -- | ||||
| Total Finance Div Other LT Assets | -- | ||||
| Total Other Assets | -49.19% | ||||
| Total Assets | 514.85% | ||||
|
|
|||||
| Total Accounts Payable | 159.94% | ||||
| Total Accrued Expenses | 0.12% | ||||
| Short-term Debt | -- | ||||
| Current Portion of Long-Term Debt/Capital Leases | -- | ||||
| Finance Division Debt Current | -- | ||||
| Total Finance Division Other Current Liabilities | 139.82% | ||||
| Total Other Current Liabilities | 139.82% | ||||
| Total Current Liabilities | 17.24% | ||||
|
|
|||||
| Total Current Liabilities | 17.24% | ||||
| Long-Term Debt | -- | ||||
| Short-term Debt | -- | ||||
| Capital Leases | -- | ||||
| Finance Division Debt Non Current | -- | ||||
| Total Finance Division Other Non Current Liabilities | -- | ||||
| Total Other Liabilities | -- | ||||
| Total Liabilities | -64.88% | ||||
|
|
|||||
| Common Stock & APIC | 6,699.54% | ||||
| Retained Earnings | -66.00% | ||||
| Treasury Stock & Other | -- | ||||
| Total Common Equity | 561.70% | ||||
|
|
|||||
| Preferred Stock Redeemable | -- | ||||
| Preferred Stock Non Redeemable | -- | ||||
| Preferred Stock Convertible | -- | ||||
| Preferred Stock, Others | -- | ||||
| Total Preferred Equity | -- | ||||
|
|
|||||
| Total Common Equity | 561.70% | ||||
| Total Preferred Equity | -- | ||||
| Total Minority Interest | -- | ||||
| Total Equity | 632.30% | ||||
|
|
|||||